Is Peri-operative Hyperoxemia a Risk Factor for Postoperative Complications?

Vascular Disease Clinical Trial

— HYPEROXIA  

Official title:

Is Peri-operative Hyperoxemia a Risk Factor for Postoperative Complications? A Randomised, Prospective Study in Patients Undergoing Vascular Surgery

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02562781
• Other study ID #: ÖrebroU
• Status: Completed
• Phase: Phase 3
• Start date: November 2014
• Est. completion date: January 2021

Study information

• Verified date: March 2021
• Source: Örebro University, Sweden
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients undergoing vascular surgery are at a significantly high risk of perioperative cardiovascular, cerebral and renal events compared to those undergoing non-vascular surgery. This could be because of co-morbidities that are common in this patient group. Additionally, smoking, which is common in this population, may be a contributing factor.

Oxygen therapy has been used for decades in order to reduce the risk of myocardial infarction and stroke in patients undergoing vascular surgery and pre-existing co-morbidities in the belief that increased inspired oxygen increases oxygen delivery to tissues, thereby reducing the risk for hypoxia and cell death. However, several studies published recently have questioned the routine use of high inspired oxygen concentration (hyperoxia) to improve oxygen delivery, specifically in the neonatal period but possibly even following myocardial infarction. This could be explained by the fact that increasing inspired concentrations of oxygen cause vasoconstriction in cerebral and coronary arteries, thereby reducing blood flow. Additionally, increased oxygen causes excessive production of reactive oxygen species (ROS), and repercussion injury from oxidative stress. The latter can lead to apoptosis (cell death) in myocardial or cerebral neurons. Despite the high risks of administering oxygen when not needed, it is routinely used in hospitals all over the world without a doctors prescription.

This study aims to assess peri-operative complications up to 1 year following vascular surgery in patients randomised to receive high inspired oxygen concentration (endpoint: SpO2 98 - 100%) or minimal inspired O2 concentration (endpoint: SpO2 > 90%).

Description:

Oxygen is probably one of the commonest "non-prescription" drug used in the hospital and its advantage in several situations including carbon monoxide poisoning, central hypoxia and prior to planned intubation in an acute situation are today well-established and commonly used. Oxygen has been frowned upon in the resuscitation of newborn babies because of the risk of retrolental hypoplasia, now well accepted and adopted in clinical practice. Oxygen has also been traditionally used to increase oxygen carrying capacity in patients presenting with an acute coronary syndrome (ACS), to reduce surgical site infections (SSI), to ensure adequate oxygen delivery to tissues in unconscious patients, during cardiac surgery and for postoperative management, specifically after major surgery. Thus, deliberate use of high inspiratory oxygen concentrations (e.g., 80% or above) is recommended in the treatment of specific intoxications, such as with carbon monoxide or cyanide, wherein hyperbaric oxygen should also be considered. In addition, a high oxygen fraction has been suggested to prevent adverse outcomes after surgery and anesthesia, including a reduction in wound infections and postoperative nausea and vomiting (PONV). In critically ill patients, oxygen delivery to the tissues is often compromised, and supplemental oxygen (e.g., face mask with 10 L oxygen per min) is commonly administered to patients with pneumonia, sepsis, acute coronary syndrome, or stroke - in fact, it is estimated that oxygen is given during transport in approximately one-third of all ambulance journeys.

Several reports published recently have questioned many of the "routine" uses of oxygen and some evidence even seems to point towards negative outcomes in some of these conditions. Specifically, excessive oxygen is likely to do more harm than good in the neonatal period, following cardio-pulmonary resuscitation and likely following acute myocardial infarction. Prospective, randomised studies on this important use of oxygen in the preoperative string are, however, lacking in the literature and in view of theoretical risks for hyperoxemia to several organs, the routine use of high oxygen fractions during the peri-operative phase can be questioned.

This study aims to assess peri-operative complications up to 1 year following vascular surgery in patients randomised to receive high inspired oxygen concentration (endpoint: SpO2 98 - 100%) or minimal inspired O2 concentration (endpoint: SpO2 > 90%).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 184
• Est. completion date: January 2021
• Est. primary completion date: December 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• Patients undergoing elective vascular surgery (peripheral or aortic surgery),

• No language or cognitive disability

• Written, informed consent

Exclusion Criteria:

• Patients with COPD/other lung diseases that require preoperative oxygen therapy

• Patients undergoing carotid artery surgery

Related Conditions & MeSH terms

• Postoperative Complications
• Vascular Disease
• Vascular Diseases

Intervention

Drug:
• Oxygen
Oxygen in sufficient quantity to maintain SpO2 > 98%

Other:
• Air
Supplemental Oxygen in sufficient quantity to maintain SpO2 > 90%

Locations

Country	Name	City	State
Sweden	Örebro University Hospital	Örebro
Sweden	University Hospital	Örebro

Sponsors (1)

Lead Sponsor	Collaborator
Örebro University, Sweden

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Complication (Re-operation or bleeding)	Re-operation or bleeding	0 - 30 days postoperatively
Primary	Composite morbidity	Major complications such as MACE, TIA/stroke/renal insufficiency/POCD etc	0 - 1 month postoperatively
Secondary	Long term outcome (Major complications)	Major complications	1 month to 1 year postoperatively
Secondary	Specific outcomes (Major adverse cardiac events (MACE))	Major adverse cardiac events (MACE)	0 - 1 year postoperatively
Secondary	Specific outcomes (TIA or stroke)	TIA or stroke	0 - 1 year postoperatively
Secondary	Specific outcomes (renal insufficiency including dialysis or renal failure)	renal insufficiency including dialysis or renal failure	0 - 1 year postoperatively